Surgery Partners Deal Turns Regulatory Certainty Into a 10% Clock

Surgery Partners has put an unusually clear price on something takeover announcements often leave implicit: time. The outpatient surgery operator agreed to raise HealthSpan Partners’ cash offer from $23.50 to $25 a share, while rejecting an unsolicited $28 proposal from another buyer. If the HealthSpan transaction has shareholder approval but remains open after 1 March 2027, eligible investors begin receiving $0.208333 a share each month. That is a 10% annualized return on the $25 consideration, capped at $1.61 if the deal reaches its 23 October outside date.

The amended Surgery Partners deal is therefore not a simple contest between $25 and $28. It is a contest between a signed package with financing, regulatory obligations, a ticking fee and a committed 39% shareholder, and a higher proposal that the special committee believed would take longer, face more regulatory complexity and lacked contractual protections it had requested. The lower headline number won because the board judged the probability-weighted, time-adjusted value to be higher.

That decision is instructive well beyond healthcare. A cash takeover price is not money in the bank on announcement day. It is a conditional claim whose economic value depends on the closing probability, the expected closing date, the financing structure, the remedies a buyer must accept and the amount shareholders recover if the agreement breaks. Surgery Partners has made those variables visible enough to study.

The deal now has four prices

The amended merger announcement describes the revised transaction as an enterprise value of up to approximately $6 billion. HealthSpan Partners is a contractual affiliate and supporting organization of Bon Secours Mercy Health. The combination is still expected to close in the first quarter of 2027, subject to shareholder approval, regulatory clearances and customary conditions.

The sequence matters because each number represents a different economic state rather than a clean auction ladder.

Price	What it represents	What must happen
$23.50	Original HealthSpan cash consideration announced on 26 October	Original signed merger closes
$25.00	Amended HealthSpan cash consideration	Revised signed merger closes
Up to $26.61	$25 plus as much as $1.61 in monthly ticking payments	Shareholders approve, closing extends beyond 1 March, and the deal ultimately completes by the outside date
$28.00	Updated unsolicited third-party proposal	A new agreement would need acceptable protections, financing, regulatory clearance and completion

The fourth price is the easiest to misunderstand. The $28 proposal was not the same financial instrument as the $25 signed agreement. The company said the third party’s proposal was non-binding and would be expected to take materially longer to close or might not close. It also carried more regulatory risk and did not contain contractual protections the special committee had sought. A nominal offer becomes comparable only after adjusting for those differences.

The Securities and Exchange Commission filing adds two important details. First, the revised regulatory covenant removes a materiality limitation from the buyer’s obligation to take actions needed to overcome antitrust, competition and trade-regulation impediments. Second, the company termination fee increased to approximately $149.1 million, with up to $8.25 million of expense reimbursement if Surgery Partners terminates before shareholder approval to sign a superior proposal. These provisions increase the cost of switching and make the buyer’s regulatory promise more concrete.

Why $28 can be worth less than $25

The simplest comparison discounts each offer for time. If one buyer pays $25 in a few months and another pays $28 much later, the larger number loses some present value. But discounting alone will rarely erase a 12% headline premium. Closing probability and break outcomes do the heavier work.

Imagine, for illustration rather than as a forecast, that HealthSpan’s signed $25 agreement has a 90% chance of closing in four months. Assume a failed deal leaves the shares worth $17 and use a 5% annual discount rate. The expected present value is roughly the discounted value of $22.50 from a close plus $1.70 from the failure state, or about $24.1. Now imagine that the $28 proposal has a 70% chance of closing after twelve months and the same $17 failure value. Its probability-weighted value before discounting is $24.70; after a year of discounting it is closer to $23.5. A higher offer can rationally rank below a lower signed deal when completion risk and duration are sufficiently different.

Those probabilities are hypothetical, and investors should not treat them as Block2Learn estimates. Their purpose is to show the board’s decision rule. The relevant comparison is:

expected value = closing probability × discounted consideration + failure probability × discounted break value − switching costs.

The break value is especially important for Surgery Partners. A failed transaction would return attention to a company carrying approximately 4.4 times total net debt to EBITDA under its credit agreement, while operating in a reimbursement-sensitive and regulated industry. The unaffected share price is not automatically the correct break price, because financial results, interest rates, policy expectations and the market’s assessment of the strategic review can change while a deal is pending.

This is the same discipline that applies in a cash takeover more broadly. Block2Learn’s analysis of the Ingenia Communities takeover showed how the spread between a market price and proposed cash consideration compresses conditions, time and alternative paths into one observable number. Surgery Partners goes a step further by writing part of the duration cost into the contract.

The 10% clock is compensation, not free yield

The merger amendment filed with the SEC defines the additional payment as $0.208333 a share per month. The arithmetic is direct: 10% of $25 is $2.50 a year, and one twelfth is approximately $0.208333. A partial closing month is prorated by days. Payments begin only if shareholder approval has been obtained and the transaction has not closed on or before 1 March 2027.

That condition changes the interpretation. The ticking fee does not pay investors merely because the calendar advances. It pays after the vote has removed one major condition and delay remains between approval and closing. It is therefore targeted compensation for regulatory and execution duration rather than an unconditional dividend.

The maximum $1.61 is also revealing. It would lift total eligible consideration to $26.61 at the outside date, still below the rival’s $28 headline. HealthSpan did not match the competing proposal. It made its own package more competitive by raising the base price, paying for delay and strengthening the regulatory covenant. The board accepted a structure designed to improve realized value, not merely announced value.

Investors should resist calling the 10% rate a guaranteed return. The payment depends on record dates, approval, the agreement remaining in force and the timing of closing. A broken transaction can stop the clock. Trading costs and taxes affect realized returns. The market price paid for the stock determines the investor’s actual yield; someone buying above $25 is not earning 10% on their invested capital merely because the contract uses that rate on the merger consideration.

The fee does, however, change incentives. Without compensation, a buyer benefits from keeping the purchase price fixed while regulatory review erodes its present cost. A ticking fee transfers some of that duration cost back to the buyer. It also gives shareholders a defined payment for waiting rather than forcing them to absorb every month of delay. The clause cannot eliminate uncertainty, but it can distribute it more explicitly.

Regulatory certainty is written into the covenant

The amended covenant may be economically more important than the extra $1.50 of base consideration. According to the SEC filing, HealthSpan must take any and all action necessary to eliminate antitrust, competition and trade-regulation impediments before the end date. The amendment removes a materiality limitation, and the detailed text contemplates litigation, asset divestitures, behavioral restraints, terminated relationships and other restructuring if required.

That is a strong allocation of regulatory risk. It does not guarantee clearance, because no private contract can command a regulator to approve a transaction. It does determine which party must bear more of the work and sacrifice required to seek approval. In expected-value terms, a buyer’s obligation to accept remedies can be worth more than a higher proposal that preserves broad walk-away flexibility.

Healthcare context makes that promise credible and costly. In June 2026, the Federal Trade Commission required divestitures in Ascension Health’s acquisition of AmSurg. The order required seven ambulatory surgery centers to be sold across five metropolitan areas and imposed prior-notice obligations for certain future acquisitions. The FTC alleged that local overlap could raise prices, reduce quality and weaken innovation in outpatient surgery.

Surgery Partners operates more than 200 locations across 30 states, including ambulatory surgery centers, surgical hospitals, physician practices and urgent care facilities. A national total can obscure the local nature of competition. Regulators may study individual metropolitan areas, specialties, physician referral patterns, payer negotiations and the combined system’s ability to steer cases. A buyer willing to divest assets or accept conduct restrictions reduces one source of uncertainty but may also surrender some expected synergy.

Block2Learn examined the same trade-off in the Kimberly-Clark Kenvue transaction: a remedy can protect the larger combination while changing the assets and cash flows the buyer ultimately keeps. Regulatory clearance answers whether a deal may proceed. It does not prove that the surviving economics still justify the price.

Bain is rolling control, not cashing out

The Surgery Partners deal contains a second asymmetry. Bain Capital affiliates own approximately 39% of the outstanding shares and have agreed to vote for the HealthSpan transaction. Those shares will not receive the $25 cash consideration or the ticking fee. Bain will roll its interest into the acquiring entity and remain a significant partner after closing.

Public holders and the sponsor are therefore choosing different assets. Eligible public investors exchange their shares for cash and receive defined compensation for certain delay. Bain exchanges its public-company position for private equity in the new ownership structure. The sponsor retains exposure to future growth, leverage, integration, regulation and exit value.

A rollover can align the seller sponsor with the buyer because meaningful capital remains at risk. It can also reduce the cash required at closing and signal that the incumbent owner sees value beyond the public offer. But it is not identical to an arm’s-length cash exit. Bain’s future governance rights, liquidity, valuation and downside protection may differ from those of public shareholders. The special committee’s independence and disclosure therefore matter because the controlling economic paths are not the same.

The 39% support agreement also changes transaction probability. A large committed block reduces vote uncertainty, though it does not eliminate the need for the required shareholder approval or other conditions. For an event-driven investor, ownership structure belongs in the probability model alongside regulation and financing.

This resembles the capital-structure questions in Block2Learn’s Steadfast take-private analysis. Immediate cash certainty and continued private participation are different claims on the same operating business. Comparing them requires asking who bears leverage, who controls the asset, who retains upside and when liquidity can be realized.

The operating company explains the buyer’s conviction

Surgery Partners is not being acquired solely because it has a large facility count. Its third-quarter results show the economics of the platform and the pressure points the buyer must absorb. Revenue was $815.3 million, down 0.8% year over year after the Idaho Falls divestiture. Same-facility revenue rose 6.0%, driven by a 5.8% increase in revenue per case and only 0.2% growth in same-facility cases. Adjusted EBITDA fell to $132.7 million from $136.4 million, while the company recorded a $21.1 million attributable net loss.

For the first nine months of 2026, revenue increased 2.1% to $2.475 billion. Adjusted EBITDA declined to $360.2 million from $369.3 million, and the margin slipped to 14.6% from 15.2%. Cash and equivalents stood at $354.5 million, revolver capacity was $692.8 million, and long-term debt plus current maturities was roughly $3.06 billion. These figures come from the company’s third-quarter release.

The positive signal is pricing and mix: revenue per case is rising faster than case volume. The caution is that higher same-facility revenue has not yet translated into higher consolidated EBITDA. Labor, supplies, payer mix, facility ownership changes and corporate costs can interrupt the conversion from revenue to cash earnings. A buyer funding the acquisition with new debt must improve that conversion over time.

HealthSpan and Bon Secours Mercy Health may see strategic value in combining a national outpatient platform with health-system relationships. Procedures continue moving from inpatient hospitals to lower-cost outpatient settings when clinical practice and reimbursement permit. Physician alignment, payer contracts and local referral networks can create durable volume. Yet those same networks are what regulators examine when consolidation can reduce alternatives.

CMS updates payment rates and quality requirements through the ambulatory surgical center payment system. That makes reimbursement policy part of the acquisition thesis. Higher procedure migration can support volume, while rate changes, quality reporting and site-of-service policy can alter margins. The buyer is purchasing a regulated cash-flow system, not merely buildings and operating rooms.

New debt moves the test to the private balance sheet

HealthSpan intends to finance the acquisition with cash on hand and new debt backed by secured commitments. The exact post-closing capitalization will determine whether the transaction creates flexibility or merely relocates leverage from a public company into a privately controlled structure.

Enterprise value is not equity value. Surgery Partners’ approximately $6 billion headline includes debt and other claims that must be refinanced, assumed or otherwise reflected in the transaction. Because Bain is rolling equity rather than taking cash, the buyer’s immediate funding need is lower than a full cash-out of every share. Even so, the combined entity will need enough cash earnings to service existing and acquisition debt, fund facility investment, support physician partnerships and absorb regulatory remedies.

The most useful measure after closing will not be announced synergies. It will be free cash flow after interest, taxes, maintenance capital, minority distributions and required investment. If EBITDA grows but cash interest rises more quickly, equity value can stagnate. If operational integration improves purchasing, scheduling and payer contracting while debt falls, the rollover equity can compound.

This is why the amended price should not be read as proof that Surgery Partners was undervalued at every previous market quotation. A strategic buyer can pay a control premium because it expects private governance, system integration and a longer holding period to unlock value. The realization of that value remains conditional on execution and the cost of capital. Block2Learn’s onsemi acquisition analysis reached a parallel conclusion: replacing equity dilution with cash and debt can protect ownership percentages while transferring more risk to the balance sheet.

What the market spread is really measuring

After an agreed cash deal, the target’s share price typically trades below consideration because investors require compensation for waiting and for the chance that the transaction fails. In Surgery Partners, the correct reference value changes with the calendar. Before 1 March, the base claim is $25 if the deal closes. After shareholder approval and the triggering date, accrued or expected monthly payments can lift the closing value. The maximum contractual amount is $26.61, not $28.

An investor can decompose the spread into four parts.

First is pure time value. Cash received later is worth less than cash received today. Second is closing risk: regulatory action, financing problems, litigation or failed conditions can prevent payment. Third is path value: a new bidder, a revised proposal or a superior-proposal process can lift consideration. Fourth is break value: the operating company’s stand-alone price may be materially below or occasionally above the pre-deal level if the transaction terminates.

The $149.1 million termination fee and expense reimbursement make the path to a rival more expensive. They do not prohibit a superior proposal, but a competing buyer must create enough incremental value to cover those costs and compensate for additional time and risk. The fee is therefore part of the option price on alternative bids.

Readers should also distinguish the contractual ticking fee from market carry. A stockholder buying at $24.50 and receiving $25 in four months earns a different return from one buying at $25.50 and eventually receiving $26.25 after delay. Both outcomes depend on closing. The relevant annualized return is based on the investor’s purchase price, holding period and total cash received, not the contract’s 10% label.

Three scenarios define the next stage

Scenario one: a first-quarter close near $25

Shareholders approve the transaction, regulators clear it without material delay, financing is funded and the merger closes on the expected schedule. Eligible investors receive $25 and no meaningful ticking fee. The market’s main variables become the time remaining and a narrowing residual break risk. Bain and HealthSpan begin the harder private-company task of integrating governance, financing and operating priorities.

Scenario two: approval arrives, regulation extends the clock

The vote is secured, but regulatory review or remedy negotiation pushes closing beyond 1 March. Eligible holders begin receiving $0.208333 per full month, with the final month prorated. The fee compensates time, while the amended covenant pushes the buyer to litigate, divest or accept restraints if necessary. Investors must still monitor whether required remedies weaken the economics or create operational disruption.

Scenario three: the path reopens or the agreement breaks

A third party could return with stronger protections, a higher price or a structure that qualifies as superior. Alternatively, regulation, financing, litigation or another closing condition could break the HealthSpan deal. In that state, the termination fee, expense reimbursement, support agreement and stand-alone balance sheet all matter. The $28 proposal is upside optionality, not current contractual consideration.

These scenarios should not be assigned fixed probabilities once and forgotten. Each filing, vote result, regulatory request, remedy disclosure and financing update changes the evidence. Deal analysis is a process of updating a probability tree, not memorizing a premium.

The indicators that deserve attention

The first indicator is the definitive proxy and Schedule 13E-3. They should explain the special committee’s process, financial-advisor analyses, background of negotiations, conflicts, rollover terms and the reasons the $28 proposal was rejected. Fairness analyses are not price targets, but their assumptions can reveal which operating and discount-rate variables drove the board’s decision.

Second, track the shareholder meeting and the exact approval date. The ticking payment requires approval before it becomes relevant. Third, monitor antitrust filings and any remedy language by local market and specialty. The recent FTC action involving outpatient surgery centers shows that a national transaction can turn on a small number of local overlaps.

Fourth, inspect the final financing package. Debt commitments reduce funding uncertainty, but interest cost, maturity, security and covenant flexibility determine post-close resilience. Fifth, follow Surgery Partners’ same-facility cases, revenue per case, EBITDA margin, operating cash flow and net leverage while the transaction is pending. A deal agreement does not freeze the business.

Finally, watch the trading price relative to $25, accrued ticking payments and an evidence-based break value. A price above base consideration may reflect expected monthly payments, a higher bid or both. A persistent discount may reflect time, risk or weak stand-alone expectations. The market spread is a summary; filings explain its components.

Block2Learn assessment

The Surgery Partners deal is a compact lesson in financial structure. The higher bid did not automatically win because price is only one term in a contingent contract. HealthSpan improved its offer across several dimensions: a $1.50 higher base, a 10% annualized clock after the triggering date, broader regulatory obligations and a package supported by the company’s largest shareholder. The board judged those elements more valuable than an extra $3 attached to a slower and less protected proposal.

That judgment may still prove right or wrong. A rival could strengthen its terms. Regulators could demand substantial remedies. The operating business could improve, deteriorate or generate a different stand-alone valuation. New debt could support productive investment or constrain it. The point is not that certainty always deserves any price. It is that certainty, time and contractual enforcement must be priced explicitly.

For investors, the cleanest framework is to separate announced consideration from expected realized value. Estimate the timing of each path, the probability of closing, the cash received in each state and the value of the company if the agreement breaks. Then update those inputs when evidence changes. A headline premium is a starting point, not an answer.

Continue through the Block2Learn Learning Path to connect deal spreads, capital structure, regulatory risk and company analysis within one decision framework.

This article is provided solely for informational and educational purposes and does not constitute financial or investment advice, a recommendation, or an offer or solicitation to buy or sell any financial instrument or digital asset.

Information is abundant. Structure is rare.